Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis
Zhanpeng Liang,Ting Chen,Wenxia Li,Huiqin Lai,Luzhen Li,Jiaming Wu,Huatang Zhang,Cantu Fang
DOI: https://doi.org/10.1097/md.0000000000036785
IF: 1.6
2024-01-20
Medicine
Abstract:Esophageal cancer, the sixth leading cause of cancer death in the world, is a disease with a poor prognosis [ 1 ] Surgery is a common treatment for locally advanced resectable (or potentially resectable) esophageal cancer, but the results are not satisfactory. The 5-year survival rate after surgery alone is very low, and most patients have local recurrence or distant metastasis after surgery. [ 2 , 3 ] In order to further improve the survival of patients with locally advanced esophageal cancer, a variety of new treatment programs continue to emerge. Based on OEO2 [ 4 ] and CROSS trials, [ 5 , 6 ] neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT) have replaced surgical treatment alone as the standard treatment for locally advanced esophageal cancer. Whether nCRT is better than nCT is always a concern. Previous randomized clinical trials comparing the effects of nCRT and nCT in esophageal cancer have found that chemoradiotherapy could improve local control but did not reduce the risk of distant metastasis. [ 7 , 8 ] Meanwhile, nCRT may increase the risk of postoperative complications and death, offsetting some of the benefit trend. [ 9 , 10 ] Thus, chemoradiotherapy provided a higher rate of complete histopathological response, but no statistically significant improvement in survival. Due to insufficient data provided by previous randomized trials, some previous meta-analyses included cohort studies, leading to low levels of evidence, unreliable conclusions and some major defects. [ 11 ] Moreover, meta-analyses of randomized trials do not support survival benefits of nCRT [ 12–14 ] ]. So far, the jury is still out on whether to add additional radiation therapy. However, there is no evidence that nCRT is superior to nCT. In recent years, several important trials have been published that promise to change the current treatment landscape. [ 15 , 16 ] Therefore, a rigorous and meta-analysis is necessary. We conducted a meta-analysis focusing only on randomized controlled trials to compare the efficacy and safety of nCRT versus nCT in locally advanced esophageal cancer.
medicine, general & internal